# Amy Kruse

> Amy Kruse is a seed investor at Prime Movers Lab (Washington) backing Medical and Health Care. See 15 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Prime Movers Lab](https://shizune.co/investors/profile/prime-movers-lab)
- Location: Washington, United States
- Total investments: 15
- Last investment: Mar 2026
- Lead investor: 67%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/amy-kruse-8409ab19/

Amy Kruse is a seed investor at Prime Movers Lab in Washington focused on Medical and Health Care. Amy Kruse currently works as the partner and principal biologist for Prime Movers Lab. She previously worked at Optios as the chief scientific officer.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 7 | 47% |
| Health Care | 7 | 47% |
| Biotechnology | 5 | 33% |
| Medical Device | 4 | 27% |
| Life Science | 2 | 13% |

22 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 4 | 27% |
| Series A | 4 | 27% |
| Series B | 3 | 20% |
| Funding Round | 2 | 13% |
| Convertible Note | 1 | 7% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 10 | 67% |
| United Kingdom | 1 | 7% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Gilgamesh Pharmaceuticals | Gilgamesh Pharmaceuticals focuses on developing therapeutics that target neuropsychiatric and central nervous system conditions using small molecules derived from research on psychedelic compounds. The company designs and tests compounds that aim to modulate brain pathways involved in mental health disorders while reducing hallucinogenic effects.Its pipeline includes drug candidates intended for conditions such as depression, anxiety, and substance use disorders. Gilgamesh Pharmaceuticals conducts preclinical and clinical studies to evaluate the safety, dosing, and efficacy of its compounds. The company integrates medicinal chemistry, neuroscience, and clinical research to support drug development and regulatory progression. | $60M | Series A | Mar 24, 2026 |  |
| NextSense | NextSense unlocks brain health with real-world data insights and practical, scientific wisdom for daily living. It aims to catalyze brain health in science and culture. The company was founded in 2020 and is headquartered in Mountain View, California. | $16.3M | Series A | Nov 11, 2025 |  |
| Feel Therapeutics | Feel Therapeutics is a digital precision medicine company delivering objective data and passive measurement for mental health. The company develops physiological and digital biomarkers and therapeutics for mental health. Its Feel data monitoring device leverages five embedded sensors via the wristband. Feel collects biometric data and analyzes themusing the latest cutting-edge methods of computer science to develop digital biomarkers.Feel Therapeutics, formerly known as Sentio Solutions. | $830K | Convertible Note | Apr 10, 2024 |  |
| Motif Neurotech | Motif Neurotech is a company that develops minimally invasive bioelectronic implants for monitoring and treating severe mental illnesses. | $18.8M | Series A | Jan 24, 2024 |  |
| TARA Mind | Tara Mind provides safe and equitable access to psychedelic-assisted therapy in order to prevent mental health crises. | $8M | Seed | Jan 23, 2024 |  |
| Feel Therapeutics | Feel Therapeutics is a digital precision medicine company delivering objective data and passive measurement for mental health. The company develops physiological and digital biomarkers and therapeutics for mental health. Its Feel data monitoring device leverages five embedded sensors via the wristband. Feel collects biometric data and analyzes themusing the latest cutting-edge methods of computer science to develop digital biomarkers.Feel Therapeutics, formerly known as Sentio Solutions. |  |  | Jan 09, 2024 |  |
| Dimension Inx | Dimension Inx focuses on creating advanced biomaterials and 3D-printed implants that fundamentally change human disease and debilitation. It specializes in the fields of additive manufacturing, 3D-printing, biomaterials, and manufacturing. It was founded in 2017 and headquartered in Chicago, Illinois. | $12M | Series A | Feb 01, 2023 |  |
| Morphoceuticals | Morphoceuticals is a biotechnology platform establishing a basis for limb regeneration and the discovery of regenerative interventions. It focuses on the understanding of the biophysical mechanisms that implement decision-making during complex pattern regulation and utilizes bioelectric dynamics to change developmental patterning and spurregeneration in organisms that do not regenerate tissues or organs. It helps medical researchers to treat complicated health states through limb regeneration, improving amputation stump health, promoting organ regeneration, and the treatment of channelopathies. | $8M | Seed | Jan 23, 2023 |  |
| Gilgamesh Pharmaceuticals | Gilgamesh Pharmaceuticals focuses on developing therapeutics that target neuropsychiatric and central nervous system conditions using small molecules derived from research on psychedelic compounds. The company designs and tests compounds that aim to modulate brain pathways involved in mental health disorders while reducing hallucinogenic effects.Its pipeline includes drug candidates intended for conditions such as depression, anxiety, and substance use disorders. Gilgamesh Pharmaceuticals conducts preclinical and clinical studies to evaluate the safety, dosing, and efficacy of its compounds. The company integrates medicinal chemistry, neuroscience, and clinical research to support drug development and regulatory progression. | $39M | Series B | Dec 15, 2022 |  |
| Cognixion | Cognixion is a computer software company that specializes in the fields of artificial intelligence, machine learning, and biotechnology. It features a sensory communication system that enables people to communicate using a brain-computer interface that translates brainwaves directly into communication.The company was founded in 2014 andheadquartered in Santa Barbara, California. | $12M | Seed | Nov 16, 2021 |  |

10 of 15 investments shown.

## Co-investors
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund, 4 deals together
- [Palo Santo Fund](https://shizune.co/investors/profile/palo-santo-venture-fund) — VC Fund, 3 deals together
- [What If Ventures](https://shizune.co/investors/profile/what-if-ventures) — VC Fund, 3 deals together
- [Anthemis Exponential Ventures](https://shizune.co/investors/profile/anthemis-exponential-ventures) — VC Fund, 2 deals together
- [Dolby Family Ventures](https://shizune.co/investors/profile/dolby-family-ventures) — VC Fund, 2 deals together
- [Empath Ventures](https://shizune.co/investors/profile/empath-ventures) — VC Fund, 2 deals together

## About Prime Movers Lab

VC Fund · Jackson, United States

Prime Movers Lab is a venture capital firm that seeks to invest in startups reinventing energy, transportation, infrastructure, manufacturing, human augmentation, and agriculture.

5 contacts available at Prime Movers Lab.

| Name | Title | Profile |
| --- | --- | --- |
| Anton Brevde | Chief of Staff | https://shizune.co/investors/profile/anton-brevde |
| Brad Pruente | Partner, Prime Movers Lab | https://shizune.co/investors/profile/brad-pruente-f98d |
| Amy Kruse | Partner & Principal Biologist | https://shizune.co/investors/profile/amy-kruse |
| Dakin Sloss | Founder & General Partner | https://shizune.co/investors/profile/dakin-sloss |
| Gabrielle Sloss | Venture Partner | https://shizune.co/investors/profile/gabrielle-sloss |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Amy Kruse invest in?

Amy Kruse invests primarily in Medical, Health Care and Biotechnology startups, most often at Seed and Series A stage. Most of the 15 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Amy Kruse last invest?

The most recent investment recorded for Amy Kruse closed in Mar 2026. Shizune tracks 15 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co